Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08103402 · 1 trial · 4 indications
Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional)
Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional)
Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional)
Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional).
Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional).
Part C: Cohort 9
Part C: Cohort 9
Part D: Cohort 10 (optional)
Part F: Cohort 13 (optional)
Part F: Cohort 13 (optional)
| Arm | Type | Description |
|---|---|---|
| Part A: Cohorts 1, 2 and Optional Cohort 3 | PLACEBO_COMPARATOR | PF-08103402 as suspensions (Cohorts 1 and 2)/tablets (Optional Cohort 3) or matching placebo as a single oral dose on Day 1 of each period |
| Part B: Cohorts 4, 5, 6, 7, and Optional Cohort 8 | PLACEBO_COMPARATOR | PF-08103402 as tablets or matching placebo given once daily oral doses from Day 1 through Day 14. |
| Part C: Cohort 9 | OTHER | PF-08103402 as a single oral dose as tablets on Day 1 of each period |
| Part D: Cohort 10 (Optional) | OTHER | PF-08103402 as a single oral dose as tablets on Day 1. |
| Part E: Cohorts 11 (Optional) and 12 (Optional) | PLACEBO_COMPARATOR | PF-08103402 as tablets or corresponding placebo as oral doses from Day 1 through Day 14. |
| Part F: Cohort 13 (Optional) | OTHER | Period 1: Single oral dose of midazolam on Day 1. Period 2: Once daily oral dose of PF-08103402 as tablets from Day 1 through Day 14 and a single oral dose of midazolam on Day 14 after the administration of PF-08103402. |
| Name | Type | Description |
|---|---|---|
| PF-08103402 | DRUG | Oral suspension (Parts A to F); Tablets (Parts C and F only) |
| Placebo | DRUG | Oral suspension (Parts A, B and E). |
| Midazolam | DRUG | Oral syrup |
Key Inclusion criteria (Parts A, B, C, D and F): 1. Are males or females who can no longer have children, 2. Are 18 to 65 years old, 3. Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). For Part A (Optional group or...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
PF-08103402 is an investigational small molecule developed by Pfizer, Inc. for the treatment of asthma. It is currently in Phase 1 clinical development and has not been approved by the FDA. Pfizer is evaluating the drug in a single recruiting trial that includes healthy adults and adults with mild to moderate asthma.
PF-08103402 is being studied as a potential treatment for asthma, a respiratory condition. The Phase 1 trial enrolls adults with mild to moderate asthma as well as healthy participants. Because the drug is still in early clinical development, its use in asthma remains investigational and it is not available as a prescribed therapy.
Pfizer, Inc. is developing PF-08103402. The company trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the Phase 1 study evaluating the drug in healthy adults and adults with mild to moderate asthma.
PF-08103402 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The ongoing Phase 1 trial is designed to assess how different amounts of the study medicine are tolerated and how it acts in the body.
PF-08103402 is being evaluated in one clinical trial, NCT07660731, titled a study to learn how different amounts of the study medicine called PF-08103402 are tolerated and act in the body in healthy adults or adults with mild to moderate asthma. The trial is recruiting, is placebo controlled, randomized, and double blind, and plans to enroll 133 participants in the United States.